AAV Nanoparticle Chimera for Brain Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The delivery of therapeutics across the blood-brain barrier (BBB) remains a significant challenge due to low delivery efficiency and significant off-target accumulation, particularly in the liver.
Innovation Solution
A gene-targeting chimera is developed, comprising adeno-associated viruses (AAVs), nanoparticles, a uniform silica shell coating, and linking chemistry to covalently attach AAVs and nanoparticles, allowing for controlled targeting and delivery of therapeutics to the brain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional delivery methods (PEG grafting, targeting moieties, extracellular vesicles) are used to deliver therapeutics across the blood-brain barrier, then some delivery capability is achieved, but delivery efficiency remains low (≤1% of injected dose) and significant off-target accumulation occurs in the liver
Solution Approach 1:
The patent employs a composite delivery system combining adeno-associated viruses (AAVs) with nanoparticles. The AAV provides biological targeting capability to cross the blood-brain barrier, while the nanoparticle component enables magnetic guidance and enhanced stability. This composite structure achieves delivery efficiency of approximately 4% of injected dose to the brain while minimizing liver accumulation, resolving the contradiction between delivery efficiency and off-target accumulation
Solution Approach 2:
The patent introduces a uniform silica shell coating as an intermediary layer between the nanoparticle core and the AAV. This silica shell facilitates controlled attachment of AAVs to nanoparticles while maintaining their individual functions. The linking chemistry covalently attaches AAVs to the nanoparticle surface, creating a stable intermediate structure that enables both magnetic guidance and viral targeting, thereby improving delivery efficiency while reducing off-target effects
2Reliability
If AAVs are used alone for gene delivery, then tissue targeting capability is provided, but delivery efficiency across the blood-brain barrier remains limited and liver accumulation occurs
Solution Approach 1:
The patent merges AAVs with magnetic nanoparticles into a unified chimera structure. The AAV retains its natural tissue targeting capability while the nanoparticle component adds magnetic guidance functionality. This merging allows the system to achieve approximately 4% delivery efficiency of injected dose to the brain, significantly improving upon AAVs alone while maintaining their inherent targeting properties
Solution Approach 2:
The chimera structure provides multi-functionality: AAVs contribute biological targeting and gene delivery capability, nanoparticles provide magnetic responsiveness for external guidance, and the silica shell enables stable covalent attachment. This universal design allows a single system to perform multiple functions simultaneously, enhancing brain delivery efficiency while reducing reliance on high doses that would increase liver accumulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimera achieves a delivery efficiency of approximately 4% of the injected dose to the brain, which is significantly higher than previous reports, while minimizing accumulation in the liver, thus overcoming the limitations of existing delivery methods.
Implementation Method 1
a uniform silica shell coating over the nanoparticle
Implementation Method 2
a linking chemistry covalently attaching the at least one AAV and the nanoparticle
Implementation Method 3
a location of the gene-targeting chimera in a mammal may be controlled by at least one of a serotype of the AAV or a magnetic field
Data Source
AI summary
A gene-targeting chimera including an adeno-associated virus (AAV) and a nanoparticle is disclosed. The nanoparticle may include a silica shell coating. The AAV and nanoparticle may be covalently attached using a linking chemistry. The nanoparticle may include a magnetic nanoparticle (MNP), a magnetic nanodisc (MND), or a quantum dot (QD). The gene-targeting chimeras may retain the tropism of original AAV serotype used. Additionally, The gene-targeting chimeras may also be able to be controlled using a magnetic field. The gene-targeting chimeras may enable nanoparticle delivery to specific cells and organs.